Oncology Clinical Trials Key Considerations: Planning For Success

Chief Scientific Officer Gabriel Kremmidiotis and CEO Yvonne Lungershausen from Avance Clinical delve into key strategies for conducting successful early-phase oncology trials for biotechs. They highlight Avance Clinical’s extensive experience in delivering tailored oncology trials, emphasizing the Australian regulatory advantages, such as no IND requirement and the 43.5% R&D tax rebate.

The presentation outlines how Avance Clinical supports biotechs from trial design to seamless US transitions, offering insights into adaptive trial designs, patient population selection, and emerging oncology therapeutics like CAR-T and gene therapies. With a strong global reach and end-to-end service capabilities, Avance Clinical ensures biotechs achieve rapid and cost-effective trial outcomes while maintaining high-quality data recognized by global regulatory bodies.